Developing a new vaccine adjuvant to enhance immune response against gonorrhea and aspergillosis
VESIVAX TLR7 FORMULA
This study is working on a new helper ingredient for vaccines called ME-M-006, which aims to make vaccines more effective against infections like gonorrhea and a type of fungus, so that people can have better protection when they get vaccinated.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Molecular Express, INC. NIH-funded |
| Lab location | 1 site (Rancho Dominguez, United States) |
| Project ID | NIH-11203954 on NIH RePORTER |
What this research studies
This research focuses on creating a vaccine adjuvant called ME-M-006, which is designed to boost the immune response against infections caused by Neisseria gonorrhoeae and Aspergillus fumigatus. The adjuvant is formulated using a TLR7 agonist within a liposomal platform, which helps in delivering the vaccine more effectively. The project involves optimizing the manufacturing process, conducting stability tests, and characterizing the product to ensure its efficacy and safety for future vaccine applications.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk for gonorrhea or aspergillosis, including those with compromised immune systems or specific health conditions that make them susceptible to these infections.
Not a fit: Patients who are not at risk for gonorrhea or aspergillosis, or those who have already been vaccinated against these infections, may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective vaccines that provide better protection against gonorrhea and aspergillosis.
How similar studies have performed: Previous research has shown promise in using TLR7 agonists as vaccine adjuvants, indicating that this approach has potential for success.
Where this research is happening
Rancho Dominguez, United States
- Molecular Express, INC. — Rancho Dominguez, United States (Active)
Researchers
- Principal investigator: Ho, Samon — Molecular Express, INC.
- Study coordinator: Ho, Samon
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.